Price Action Don’t Lie: Sucampo Pharmaceuticals, Inc. Can’t Be More Risky. Trades Sigfnicicantly Lower

Price Action Don't Lie: Sucampo Pharmaceuticals, Inc. Can't Be More Risky. Trades Sigfnicicantly Lower

The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) is a huge mover today! About 626,037 shares traded hands or 28.04% up from the average. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has risen 56.48% since April 27, 2016 and is uptrending. It has outperformed by 51.25% the S&P500.
The move comes after 7 months negative chart setup for the $789.76 million company. It was reported on Nov, 30 by Barchart.com. We have $15.26 PT which if reached, will make NASDAQ:SCMP worth $47.39 million less.

Analysts await Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report earnings on March, 14. They expect $0.44 earnings per share, 0.00% or $0.00 from last year’s $0.44 per share. SCMP’s profit will be $21.41 million for 9.22 P/E if the $0.44 EPS becomes a reality. After $0.28 actual earnings per share reported by Sucampo Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 57.14% EPS growth.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Ratings Coverage

Out of 9 analysts covering Sucampo Pharma (NASDAQ:SCMP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Sucampo Pharma has been the topic of 21 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was maintained by WallachBeth Capital with “Hold” on Thursday, August 27. The stock has “Buy” rating given by Roth Capital on Thursday, October 29. Mizuho upgraded the stock to “Buy” rating in Wednesday, April 20 report. UBS initiated Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rating on Tuesday, February 9. UBS has “Buy” rating and $20 price target. On Wednesday, September 7 the stock rating was initiated by Northland Capital with “Outperform”. The company was maintained on Wednesday, August 26 by Maxim Group. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) earned “Neutral” rating by Mizuho on Friday, October 9. TH Capital reinitiated it with “Buy” rating and $29.0 target price in Thursday, October 29 report. The company was maintained on Monday, January 18 by Mizuho. H.C. Wainwright initiated Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rating on Monday, August 24. H.C. Wainwright has “Buy” rating and $31 price target.

According to Zacks Investment Research, “Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.”

Insitutional Activity: The institutional sentiment is 0.98 in Q2 2016. Its the same as in 2016Q1. The ratio is flat, as 17 funds sold all Sucampo Pharmaceuticals, Inc. shares owned while 46 reduced positions. only 22 funds bought stakes while 40 increased positions. They now own 17.83 million shares or 12.41% less from 20.36 million shares in 2016Q1.
Zacks Inv reported 10,050 shares or 0% of all its holdings. Fincl Bank Of America Corp De accumulated 90,128 shares or 0% of the stock. Renaissance Technology Ltd Com, a New York-based fund reported 1.11M shares. Creative Planning owns 1,000 shares or 0% of their US portfolio. The New Jersey-based Prudential Fincl Inc has invested 0.01% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Ativo Cap Limited accumulated 92,023 shares or 0.25% of the stock. Proshare Advsr Lc holds 36,954 shares or 0.01% of its portfolio. Bridgeway Capital Mgmt has 0% invested in the company for 20,000 shares. Blackrock Advsrs last reported 0% of its portfolio in the stock. Swiss Bank has invested 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). National Bank Of New York Mellon Corp last reported 0% of its portfolio in the stock. Nationwide Fund Advsr last reported 0% of its portfolio in the stock. Princeton Alpha Lp has 0.02% invested in the company for 12,616 shares. Moreover, Royal National Bank Of Canada has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 56,771 shares. Morgan Stanley last reported 0% of its portfolio in the stock.

Insider Transactions: Since November 15, 2016, the stock had 0 buys, and 2 insider sales for $2.43 million net activity. On Wednesday, November 23 Alder Matthias sold $2.40M worth of the stock or 150,000 shares. $27,514 worth of shares were sold by Smith Andrew P on Tuesday, November 15.

Another recent and important Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) news was published by Bizjournals.com which published an article titled: “Sucampo acquires exclusive option for cancer drug in deal worth up to $190 million” on January 11, 2016.

SCMP Company Profile

Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a biopharmaceutical company. The Firm focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology inflammatory disorders. The Firm operates through development and commercialization of pharmaceutical products segment. The Company’s activities are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts activities in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, United Kingdom.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment